(Q35586781)

9 August 2017

1 reference

title

Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes (English)

1 reference

9 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00370-4

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00370-4

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00370-4

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00370-4

3 April 2024

author name string

J. M. Dixon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623524

3 April 2024

J. Jackson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623524

3 April 2024

L. Renshaw

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623524

3 April 2024

W. R. Miller

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623524

3 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14623524

3 April 2024

publication date

1 September 2003

1 reference

full work available at URL

9 August 2017

https://api.elsevier.com/content/article/PII:S0960076003003704?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00370-4

https://api.elsevier.com/content/article/PII:S0960076003003704?httpAccept=text/plain

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00370-4

The Journal of Steroid Biochemistry and Molecular Biology

3 April 2024

published in

1 reference

9 August 2017

volume

86

1 reference

9 August 2017

issue

3-5

1 reference

9 August 2017

page(s)

295-299

1 reference

Chemotherapy before and after mastectomy in stage III breast cancer

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Treatment of breast cancer in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Letrozole as primary medical therapy for locally advanced and large operable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Conservation surgery after primary chemotherapy in large carcinomas of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Breast conservative surgery: is it appropriate for locally advanced breast cancer following downstaging by neoadjuvant chemotherapy? A pathological assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Neoadjuvant endocrine therapy of breast cancer: a surgical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Should surgery remain the initial treatment of “operable” breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900370-4

7 January 2021

The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study

14

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00370-4

Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy

3 April 2024

19

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00370-4

3 April 2024

Identifiers

1 reference

9 August 2017

1 reference